Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Mohube Betty Maepa"'
Publikováno v:
Pharmaceutics, Vol 16, Iss 11, p 1360 (2024)
Over 80% of the world’s deadliest pandemics are caused by viral infections, and vaccination remains the most effective way to prevent these infections from spreading. Since the discovery of the first vaccine over two centuries ago, several vaccine
Externí odkaz:
https://doaj.org/article/9e7a32b3cc0942b89de5bd4d6e755def
Autor:
Ridhwaanah Jacobs, Makafui Dennis Dogbey, Njabulo Mnyandu, Keila Neves, Stefan Barth, Patrick Arbuthnot, Mohube Betty Maepa
Publikováno v:
Microorganisms, Vol 11, Iss 12, p 2985 (2023)
Hepatitis B virus (HBV) has afflicted humankind for decades and there is still no treatment that can clear the infection. The development of recombinant adeno-associated virus (rAAV)-based gene therapy for HBV infection has become important in recent
Externí odkaz:
https://doaj.org/article/d0c6413a36ca492399e5c5715e39fed7
Publikováno v:
Virology Journal, Vol 18, Iss 1, Pp 1-12 (2021)
Abstract Despite the five decades having passed since discovery of the hepatitis B virus (HBV), together with development of an effective anti-HBV vaccine, infection with the virus remains a serious public health problem and results in nearly 900,000
Externí odkaz:
https://doaj.org/article/f2cf3259d805455e928b726cf86a410b
Autor:
Shonisani Wendy Limani, Njabulo Mnyandu, Abdullah Ely, Reubina Wadee, Anna Kramvis, Patrick Arbuthnot, Mohube Betty Maepa
Publikováno v:
Viruses, Vol 13, Iss 11, p 2247 (2021)
The paucity of animal models that simulate the replication of the hepatitis B virus (HBV) is an impediment to advancing new anti-viral treatments. The work reported here employed recombinant adeno-associated viruses (AAVs) to model HBV subgenotype A1
Externí odkaz:
https://doaj.org/article/689e6cf075b94dd7a793c5b0db69c232
Autor:
Tristan Scott, Buhle Moyo, Samantha Nicholson, Mohube Betty Maepa, Koichi Watashi, Abdullah Ely, Marc S. Weinberg, Patrick Arbuthnot
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Management of infection with hepatitis B virus (HBV) remains a global health problem. Persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is responsible for modest curative efficacy of currently licensed drug
Externí odkaz:
https://doaj.org/article/a6a126a42f17449db43d6d0992861f02
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 7, Iss C, Pp 190-199 (2017)
Chronic infection with hepatitis B virus (HBV) remains a problem of global significance and improving available treatment is important to prevent life-threatening complications arising in persistently infected individuals. HBV is susceptible to silen
Externí odkaz:
https://doaj.org/article/290ae3df64f449aeaf8068db20c8217f
Autor:
Fiona van den Berg, Shonisani Wendy Limani, Njabulo Mnyandu, Mohube Betty Maepa, Abdullah Ely, Patrick Arbuthnot
Publikováno v:
Viruses, Vol 12, Iss 8, p 851 (2020)
Infection with hepatitis B virus (HBV) remains a global health challenge. Approximately 292 million people worldwide are chronically infected with HBV and the annual mortality from the infection is approaching 900,000. Despite the availability of an
Externí odkaz:
https://doaj.org/article/746cafca473a452299af96d826bc26ce
Publikováno v:
Expert Opinion on Therapeutic Targets. 25:451-466
Introduction: Current therapy for infection with hepatitis B virus (HBV) rarely clears the virus, and viremia commonly resurges following treatment withdrawal. To prevent serious complications of t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4eb70b0e3dea19385a3d8aded6e672e
https://doi.org/10.1080/14728222.2021.1915990
https://doi.org/10.1080/14728222.2021.1915990
Publikováno v:
Current Opinion in HIV and AIDS. 15:200-207
Purpose of review The available vaccine and therapies against hepatitis B virus (HBV) rarely eliminate chronic infection with the virus. High mortality resulting from complicating cirrhosis and hepatocellular carcinoma makes improving anti-HBV therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a9da7dad349500497ce6a178816d80
https://doi.org/10.1097/coh.0000000000000623
https://doi.org/10.1097/coh.0000000000000623
Publikováno v:
Gene therapy.
Available treatment for chronic hepatitis B virus (HBV) infection offers modest functional curative efficacy. The viral replicative intermediate comprising covalently closed circular DNA (cccDNA) is responsible for persistent chronic HBV infection. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95415b058dadd8d2dd340eb54a85b95b
https://pubmed.ncbi.nlm.nih.gov/35606493
https://pubmed.ncbi.nlm.nih.gov/35606493